Deutsche Bank40th Annual Health Care Conference on Thursday, May 7, 2015from 8:40 to 9:15 a.m. ETat the Intercontinental Hotelin Boston.
Bank of America Merrill Lynch2015 Health Care Conferenceon Tuesday, May 12, 2015from 4:20 to 4:50 p.m. PTat the Encore at the Wynn Hotelin Las Vegas.
To access the live webcasts of bluebird bio’s presentations, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and T cell-based
immunotherapy. bluebird bio’s clinical programs include Lenti-D™,
currently in a Phase 2/3 study, called the Starbeam Study, for the
treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®,
currently in three clinical studies: a global Phase 1/2 study, called
the Northstar Study, for the treatment of beta-thalassemia major; a
single-center Phase 1/2 study in
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated milestones
related to the Company’s product candidates. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in the Company’s clinical studies, the risk that
the results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our collaboration
Source: bluebird bio, Inc.
bluebird bio, Inc.
Jim DeTore, 339-499-9355
Chief Financial Officer
Pure Communications, Inc.
Dan Budwick, 973-271-6085